Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome  Macarena Alpañés, M.D., Manuel.

Slides:



Advertisements
Similar presentations
Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States  David B. Seifer, M.D., Valerie.
Advertisements

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome  Madelon van Wely, Ph.D.,
Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women.
Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the.
Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice  Lysanne.
Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M
Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome  Anuja Dokras, M.D., Ph.D., Shailly Saini,
Endocrine and cardiometabolic cord blood characteristics of offspring born to mothers with and without polycystic ovary syndrome  Nadine M.P. Daan, M.D.,
The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report  Ricardo Azziz, M.D., M.P.H., Enrico Carmina,
Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis  Héctor F. Escobar-Morreale, M.D., Ph.D., Manuel Luque-Ramírez,
Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome  Elisabeth Lerchbaum,
Comparison of hormonal and metabolic markers after a high-fat, Western meal versus a low-fat, high-fiber meal in women with polycystic ovary syndrome 
Risk of obstructive sleep apnea in obese and nonobese women with polycystic ovary syndrome and healthy reproductively normal women  Babak Mokhlesi, M.D.,
Kalliopi Kotsa, M. D. , Ph. D. , Maria P. Yavropoulou, M. D
Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters  Enrico Carmina, M.D., Francesco.
Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome  Anuja Dokras, M.D., Ph.D., Shailly Saini,
Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow-up study  Cem Celik, M.D., Nicel.
The spectrum of androgen excess disorders
Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome 
Insulin resistance in oligomenorrheic infertile women with non-polycystic ovary syndrome  Shirei Ohgi, M.D., Koji Nakagawa, M.D., Ph.D., Rieko Kojima,
Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study  Angela Kerchner, B.A., Whitney Lester,
Robert A. Wild, M. D. , Manfredi Rizzo, M. D. , Sheri Clifton, Ph. D
Cardiovascular and metabolic profiles of offspring conceived by assisted reproductive technologies: a systematic review and meta-analysis  Xiao-Yan Guo,
Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels 
Study of circulating hepcidin in association with iron excess, metabolic syndrome, and BMP-6 expression in granulosa cells in women with polycystic ovary.
Expression of growth differentiation factor-9 and bone morphogenetic protein-15 in oocytes and cumulus granulosa cells of patients with polycystic ovary.
Rebecca A. Feldman, M. D. , Kathleen O'Neill, M. D. , Samantha F
Predictive factors of health-related quality of life in patients with polycystic ovary syndrome: a structural equation modeling approach  Fatemeh Bazarganipour,
Role of androgen-mediated enhancement of erythropoiesis in the increased body iron stores of patients with polycystic ovary syndrome  Héctor F. Escobar-Morreale,
Evolutionary determinants of polycystic ovary syndrome: part 1
Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular.
Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis 
Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the.
Zehong Zhou, Rong Li, Jie Qiao  Reproductive BioMedicine Online 
Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens 
Paweł Jóźków, M. D. , Ph. D. , Marek Mędraś, M. D. , Ph. D
The determinants of insulin sensitivity, β-cell function, and glucose tolerance are different in patients with polycystic ovary syndrome than in women.
Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis  Shiqin Zhu, M.D., Bingqian Zhang, M.D.,
Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular.
Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity  Jean-Patrice Baillargeon, M.D.,
Prevalence of polycystic ovary syndrome in Chinese obese women of reproductive age with or without metabolic syndrome  Peiwen Liang, M.D., Liuqing Xi,
Increased secretion of amylin in women with polycystic ovary syndrome
Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity 
ACC/AHA 2017 definition of high blood pressure: implications for women with polycystic ovary syndrome  Lucas Bandeira Marchesan, B.Sc., Poli Mara Spritzer,
Metabolism of triglyceride-rich lipoproteins and lipid transfer to high-density lipoprotein in young obese and normal-weight patients with polycystic.
Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment  Richard Fleming, Ph.D.,
Banu Ucar, M. D. , Volkan Noyan, M. D. , Osman Caglayan, M. D
Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial  Antoni J. Duleba, M.D.,
Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women  Hong Zang, M.D., Kjell Carlström,
Higher PDCD4 expression is associated with obesity, insulin resistance, lipid metabolism disorders, and granulosa cell apoptosis in polycystic ovary syndrome 
Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin  Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.
Manuel Maliqueo, Ph. D. , Bárbara Echiburú, Ph. D
Association of increased total antioxidant capacity and anovulation in nonobese infertile patients with clomiphene citrate–resistant polycystic ovary.
Paolo Moghetti, M.D.  Fertility and Sterility 
Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome  Madelon van Wely, Ph.D.,
Rupal Shroff, B. S. , Craig H. Syrop, M. D. , William Davis, M. D
Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions  Kristen Farrell, M.S.,
Increased acylation-stimulating protein, C-reactive protein, and lipid levels in young women with polycystic ovary syndrome  Yuwen Wu, M.D., Jianhua Zhang,
Tsan-Hon Liou, M. D. , Ph. D. , Jen-Hung Yang, M. D. , Ph. D
David H. Barad, M.D., M.S., Norbert Gleicher, M.D. 
Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation  Reshef.
Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients  Artemis Karkanaki,
Endometrial gene expression in the window of implantation is altered in obese women especially in association with polycystic ovary syndrome  José Bellver,
Decrease in adiponectin levels in women with polycystic ovary syndrome after an oral glucose tolerance test  Dimitrios Panidis, M.D., Ph.D., Dimitrios.
Increased risk of depressive disorders in women with polycystic ovary syndrome  Elizabeth Hollinrake, B.S., Alison Abreu, M.D., Michelle Maifeld, R.N.C.,
Hyperinsulinemia and circulating dehydroepiandrosterone sulfate in white and Mexican American women with polycystic ovary syndrome  Robert P. Kauffman,
Androgen responses to adrenocorticotropic hormone infusion among individual women with polycystic ovary syndrome  Kevin H. Maas, M.D., Ph.D., Sandy Chuan,
Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome  Basak Yildirim, M.D., Nuran Sabir,
Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels 
Diabetes mellitus and insulin resistance in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis 
Presentation transcript:

Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome  Macarena Alpañés, M.D., Manuel Luque-Ramírez, M.D., Ph.D., M. Ángeles Martínez-García, Ph.D., Elena Fernández-Durán, B.S., Francisco Álvarez-Blasco, M.D., Ph.D., Héctor Francisco Escobar-Morreale, M.D., Ph.D.  Fertility and Sterility  Volume 103, Issue 3, Pages 795-801.e2 (March 2015) DOI: 10.1016/j.fertnstert.2014.12.105 Copyright © 2015 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Influence of adrenal hyperandrogenism (AH) and obesity on indexes of glucose metabolism. Data are expressed as mean ± SD of the means and were submitted to a two-way general linear model introducing age as a covariate. The shaded areas represent the 95% confidence intervals of 147 healthy control subjects. To convert to SI units, multiply glucose by 0.0555 (results in nmol/L), insulin by 6.945 (results in pmol/L), and DHEAS by 0.002714 (results in μmol/L). AUC = area under the curve. PCOS = polycystic ovary syndrome. *P<.05 for the difference between AH-PCOS and non-AH-PCOS women. †P<.05 for the difference between obese and nonobese PCOS women. ‡P<.05 for the interaction between AH and obesity. Fertility and Sterility 2015 103, 795-801.e2DOI: (10.1016/j.fertnstert.2014.12.105) Copyright © 2015 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Influence of adrenal hyperandrogenism and obesity on serum lipids. Data are expressed as mean ± SD of the means and were submitted to a two-way general linear model introducing age as a covariate. The shaded areas represent the 95% confidence intervals of 147 healthy control subjects. To convert to SI units, multiply cholesterol by 0.0259 (results in mmol/L), triglycerides by 0.0113 (results in mmol/L), and DHEAS by 0.002714 (results in μmol/L). HDL = high-density lipoprotein; LDL = low-density lipoprotein; other abbreviations as in Figure 1. †P<.05 for the difference between obese and nonobese PCOS women. ‡P<.05 for the interaction between AH and obesity. Fertility and Sterility 2015 103, 795-801.e2DOI: (10.1016/j.fertnstert.2014.12.105) Copyright © 2015 American Society for Reproductive Medicine Terms and Conditions

Supplemental Figure 1 Influence of adrenal hyperandrogenism (AH) and obesity on systolic and diastolic blood pressure. Data are expressed as mean ± SD of the means and were submitted to a two-way general linear model introducing age as a covariate. The shaded areas represent the 95% confidence intervals of 147 healthy control subjects. To convert to SI units, multiply DHEAS by 0.002714 (results in μmol/L). PCOS = polycystic ovary syndrome. †P<.05 for the difference between obese and nonobese PCOS women. Fertility and Sterility 2015 103, 795-801.e2DOI: (10.1016/j.fertnstert.2014.12.105) Copyright © 2015 American Society for Reproductive Medicine Terms and Conditions